Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report by Rohit Thummalapalli, MD, Noura J. Choudhury, MD, Fiona Ehrich, MS, Tyler Beardslee, PharmD, Danielle Brazel, MD, Shannon S. Zhang, MD, Shelby Merchant, PharmD, Monica F. Chen, MD, Glenn Heller, PhD, Suresh S. Ramalingam, MD, Sai-Hong Ignatius Ou, MD, PhD, Kathryn F. Mileham, MD, Gregory J. Riely, MD, PhD

Get full text

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers by Noura J. Choudhury, MD, Jaime L. Schneider, MD, PhD, Tejas Patil, MD, Viola W. Zhu, MD, PhD, Debra A. Goldman, MS, Soo-Ryum Yang, MD, Christina J. Falcon, MPH, Andrew Do, BS, Yunan Nie, MD, Andrew J. Plodkowski, MD, Jamie E. Chaft, MD, Subba R. Digumarthy, MD, Natasha Rekhtman, MD, PhD, Maria E. Arcila, MD, Alexia Iasonos, PhD, Sai-Hong I. Ou, MD, PhD, Jessica J. Lin, MD, Alexander Drilon, MD

Get full text